(0.20%) 5 110.20 points
(0.23%) 38 326 points
(0.12%) 15 947 points
(-0.36%) $83.55
(2.55%) $1.972
(-0.21%) $2 342.20
(-0.19%) $27.48
(2.86%) $948.45
(0.01%) $0.935
(-0.05%) $11.02
(-0.22%) $0.799
(1.85%) $93.58
Live Chart Being Loaded With Signals
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally...
Stats | |
---|---|
今日成交量 | 1.26M |
平均成交量 | 11.66M |
市值 | 417.88M |
EPS | HKD0 ( 2024-03-28 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -0.360 |
ATR14 | HKD0.00500 (0.52%) |
音量 相关性
Kintor Pharmaceutical Ltd 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Kintor Pharmaceutical Ltd 相关性 - 货币/商品
Kintor Pharmaceutical Ltd 财务报表
Annual | 2022 |
营收: | HKD0 |
毛利润: | HKD0 (0.00 %) |
EPS: | HKD-2.53 |
FY | 2022 |
营收: | HKD0 |
毛利润: | HKD0 (0.00 %) |
EPS: | HKD-2.53 |
FY | 2021 |
营收: | HKD34.23M |
毛利润: | HKD34.23M (100.00 %) |
EPS: | HKD-2.72 |
FY | 2020 |
营收: | HKD0.00 |
毛利润: | HKD0.00 (0.00 %) |
EPS: | HKD-1.640 |
Financial Reports:
No articles found.
Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited, a clinical-stage biotechnology company, engages in developing and commercializing a pipeline of small molecule and biological therapeutics for androgen-receptor-related disease areas with unmet medical needs in the People's Republic of China and internationally. The company's products pipeline include Proxalutamide, a second generation androgen receptor (AR) antagonist for the treatment of metastatic castration-resistant prostate cancer, AR positive breast cancer, and COVID-19; and Pyrilutamide, an AR antagonist for the androgenetic alopecia (AGA) and acne vulgaris treatment. Its products pipeline also comprise ALK-1 antibody for the treatment of metastatic hepatocellular carcinoma (HCC) and various solid tumours; GT20029, a topical AR-PROTAC compound for the treatment of AGA and acne vulgaris; and PD-L1/TGF-ß, a dual target antibody to treat non-small cell lung cancer, biliary tract cancer, triple negative breast cancer, and HPV-associated tumours. In addition, the company's products pipeline include Detorsertib for the treatment of metastatic solid tumours, such as breast cancer, prostate cancer, and HCC; and Hedgehog/SMO Inhibitor, an inhibitor of the hedgehog signal transduction pathway to treat blood cancer and basal-cell carcinoma. Kintor Pharmaceutical Limited was founded in 2009 and is headquartered in Suzhou, the People's Republic of China.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。